Wednesday, August 03, 2022 7:13:01 AM
Literature Database
First Hemoadsorption during Cardiopulmonary Bypass in Neonate with Complex Cardiac Malformation
Christophel-Plathier E, Mendes V, Verdy F, Mauron S, Mury C. Annals of Clinical Case Reports 2022; 7:2257
08/03/2022
New!PediatricsPeer Reviewed Published DataReduction in catecholaminesReduction in length of staySafetyImprov. resp functionImpact on organ supportCardiac surgeryCase of the weekCase reportCPBInflammatory parametersIntra-Op
Download documentDownload documentDownload document
Summary
CoW 31/2022 – This case reports on a 5 day old male full term newborn with congenital hypoplastic left heart syndrome who was scheduled for a corrective procedure.
Case presentation
His left heart syndrome involved an absent mitral valve and exceedingly small aortic annulus, ascending aorta and aortic arch. Perfusion of the aortic arch was retrograde through a persistent patent ductus arteriosus. Right ventricular systolic function was normal
Shortly after birth, the neonate required continuous positive airway pressure (CPAP) and then invasive ventilation with permissive hypercapnia
He received levosimendan 12 h before surgery, and maintenance with a prostaglandin E1 infusion
Five days after birth, the patient underwent a Norwood stage I palliation with interatrial septum resection, aortic arch reconstruction and the creation of a Blalock-Taussig shunt
Cardiopulmonary bypass (CPB) duration was 227 min, aortic cross-clamping duration 180 min. Selective cerebral perfusion was 27 min at a central core temperature of 27.8° Celsius
In order to reduce the pre-operative and intra-operative inflammatory process, a CytoSorb hemoadsorption device was pre-emptively integrated into the CPB circuit
Treatment
The CytoSorb cartridge was inserted between the oxygenator outlet (QUADROX-i neonatal HMO 11000® MAQUET) and the venous line, assisted by a roller pump slave to the blood pump
The minimum flow rate through the cartridge was 100 ml/min. The servo control was 14% of the patient’s theoretical flow, indexed to 3.0 l/min/m2 to compensate for the drop induced by CytoSorb and to ensure a flow rate of 2.4 l/min/m2 to the patient
Priming was performed using “ventilated reconstituted whole blood” to ensure homeostatic conditions at CPB initiation requiring 385 ml of blood, of which 120 ml were used for priming the CytoSorb
Measurements
Hemodynamics and requirements for vasoactive substances
Overall clinical course
Results
The patient returned to the intensive care unit (ICU) intubated with infusions of norepinephrine, dopamine and milrinone. Thereafter, hemodynamic adaptation was good, with rapid weaning off all amine infusions and definitive weaning off norepinephrine on post-operative day 5
Surgery was successful and correction was adequate, with unobstructed flow through the interatrial communication and inside the aortic arch, and with good ventricular function. Despite the severity of his condition, the baby had anuneventful post-operative course, without renal, digestive, or infectious complications
Patient Follow-up
The patient was extubated on post-operative day 6
He left the ICU on day 22 and was discharged home on day 45
Conclusion
The authors describe the clinical course post-operatively as remarkable with shortened ICU and hospital lengths of stay due to the lack of (anticipated) complications. They state that previous similar cases have required much longer support on ventilation and longer ICU stays. They also believe the expected benefits to the anti-inflammatory processes are worth the large homologous blood use
As the use of CytoSorb was the only differentiating factor, its use likely helped to reduce the pre-operative and intra-operative inflammatory process, and thereby helped with the positive clinical course and outcome. The authors conclude with stating that by reducing cytokine levels, CytoSorb may have significantly reduced catecholamine infusion time, intubation time, and ICU stay.
Recent CTSO News
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM